Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

M. Bersanelli; S. Buti; G.L. Banna; U.D. Giorgi; A. Cortellini; S.E. Rebuzzi; M. Tiseo; G. Fornarini; F. Mazzoni; S. Panni; M.D. Tursi; P.D. Marino; S. Rossetti; E. Rossi; S. Tomao; E.D. Luca; M. Sorarù; C. Mucciarini; F. Atzori; L.L. Torre; M.G. Vitale; V. Martelli; P. Sepe; V. Mollica; V. Vaccaro; G. Schinzari; C. Ficorella; F. Massari; A. Maestri; R. Sabbatini; T. Sava; M.D. Maio; E. Verzoni; G. Procopio; D. Giannarelli

doi:10.2217/imt-2019-0180

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

M. Bersanelli, S. Buti, G.L. Banna, U.D. Giorgi, A. Cortellini, S.E. Rebuzzi, M. Tiseo, G. Fornarini, F. Mazzoni, S. Panni, M.D. Tursi, P.D. Marino, S. Rossetti, E. Rossi, S. Tomao, E.D. Luca, M. Sorarù, C. Mucciarini, F. Atzori, L.L. TorreM.G. Vitale, V. Martelli, P. Sepe, V. Mollica, V. Vaccaro, G. Schinzari, C. Ficorella, F. Massari, A. Maestri, R. Sabbatini, T. Sava, M.D. Maio, E. Verzoni, G. Procopio, D. Giannarelli

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population. © 2020 Future Medicine Ltd.

Original language	English
Pages (from-to)	151-159
Number of pages	9
Journal	Immunother.
Volume	12
Issue number	2
DOIs	https://doi.org/10.2217/imt-2019-0180
Publication status	Published - 2020

Keywords

ONCOLOGIA
STUDIO CLINICO
RIS

Access to Document

10.2217/imt-2019-0180

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079909104&doi=10.2217%2fimt-2019-0180&partnerID=40&md5=323e7866ec676705265900fcf716da5d

Cite this

Bersanelli, M., Buti, S., Banna, G. L., Giorgi, U. D., Cortellini, A., Rebuzzi, S. E., Tiseo, M., Fornarini, G., Mazzoni, F., Panni, S., Tursi, M. D., Marino, P. D., Rossetti, S., Rossi, E., Tomao, S., Luca, E. D., Sorarù, M., Mucciarini, C., Atzori, F., ... Giannarelli, D. (2020). Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunother., 12(2), 151-159. https://doi.org/10.2217/imt-2019-0180

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. / Bersanelli, M.; Buti, S.; Banna, G.L.; Giorgi, U.D.; Cortellini, A.; Rebuzzi, S.E.; Tiseo, M.; Fornarini, G.; Mazzoni, F.; Panni, S.; Tursi, M.D.; Marino, P.D.; Rossetti, S.; Rossi, E.; Tomao, S.; Luca, E.D.; Sorarù, M.; Mucciarini, C.; Atzori, F.; Torre, L.L.; Vitale, M.G.; Martelli, V.; Sepe, P.; Mollica, V.; Vaccaro, V.; Schinzari, G.; Ficorella, C.; Massari, F.; Maestri, A.; Sabbatini, R.; Sava, T.; Maio, M.D.; Verzoni, E.; Procopio, G.; Giannarelli, D.

In: Immunother., Vol. 12, No. 2, 2020, p. 151-159.

Research output: Contribution to journal › Article › peer-review

Bersanelli, M, Buti, S, Banna, GL, Giorgi, UD, Cortellini, A, Rebuzzi, SE, Tiseo, M, Fornarini, G, Mazzoni, F, Panni, S, Tursi, MD, Marino, PD, Rossetti, S, Rossi, E, Tomao, S, Luca, ED, Sorarù, M, Mucciarini, C, Atzori, F, Torre, LL, Vitale, MG, Martelli, V, Sepe, P, Mollica, V, Vaccaro, V, Schinzari, G, Ficorella, C, Massari, F, Maestri, A, Sabbatini, R, Sava, T, Maio, MD, Verzoni, E , Procopio, G & Giannarelli, D 2020, 'Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study', Immunother., vol. 12, no. 2, pp. 151-159. https://doi.org/10.2217/imt-2019-0180

Bersanelli, M. ; Buti, S. ; Banna, G.L. ; Giorgi, U.D. ; Cortellini, A. ; Rebuzzi, S.E. ; Tiseo, M. ; Fornarini, G. ; Mazzoni, F. ; Panni, S. ; Tursi, M.D. ; Marino, P.D. ; Rossetti, S. ; Rossi, E. ; Tomao, S. ; Luca, E.D. ; Sorarù, M. ; Mucciarini, C. ; Atzori, F. ; Torre, L.L. ; Vitale, M.G. ; Martelli, V. ; Sepe, P. ; Mollica, V. ; Vaccaro, V. ; Schinzari, G. ; Ficorella, C. ; Massari, F. ; Maestri, A. ; Sabbatini, R. ; Sava, T. ; Maio, M.D. ; Verzoni, E. ; Procopio, G. ; Giannarelli, D. / Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. In: Immunother. 2020 ; Vol. 12, No. 2. pp. 151-159.

@article{d9b7691bde0e4ce69bf3ba0873b8def2,

title = "Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study",

abstract = "Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population. {\textcopyright} 2020 Future Medicine Ltd.",

keywords = "ONCOLOGIA, STUDIO CLINICO, RIS",

author = "M. Bersanelli and S. Buti and G.L. Banna and U.D. Giorgi and A. Cortellini and S.E. Rebuzzi and M. Tiseo and G. Fornarini and F. Mazzoni and S. Panni and M.D. Tursi and P.D. Marino and S. Rossetti and E. Rossi and S. Tomao and E.D. Luca and M. Sorar{\`u} and C. Mucciarini and F. Atzori and L.L. Torre and M.G. Vitale and V. Martelli and P. Sepe and V. Mollica and V. Vaccaro and G. Schinzari and C. Ficorella and F. Massari and A. Maestri and R. Sabbatini and T. Sava and M.D. Maio and E. Verzoni and G. Procopio and D. Giannarelli",

year = "2020",

doi = "10.2217/imt-2019-0180",

language = "English",

volume = "12",

pages = "151--159",

journal = "Immunother.",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

AU - Bersanelli, M.

AU - Buti, S.

AU - Banna, G.L.

AU - Giorgi, U.D.

AU - Cortellini, A.

AU - Rebuzzi, S.E.

AU - Tiseo, M.

AU - Fornarini, G.

AU - Mazzoni, F.

AU - Panni, S.

AU - Tursi, M.D.

AU - Marino, P.D.

AU - Rossetti, S.

AU - Rossi, E.

AU - Tomao, S.

AU - Luca, E.D.

AU - Sorarù, M.

AU - Mucciarini, C.

AU - Atzori, F.

AU - Torre, L.L.

AU - Vitale, M.G.

AU - Martelli, V.

AU - Sepe, P.

AU - Mollica, V.

AU - Vaccaro, V.

AU - Schinzari, G.

AU - Ficorella, C.

AU - Massari, F.

AU - Maestri, A.

AU - Sabbatini, R.

AU - Sava, T.

AU - Maio, M.D.

AU - Verzoni, E.

AU - Procopio, G.

AU - Giannarelli, D.

PY - 2020

Y1 - 2020

N2 - Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population. © 2020 Future Medicine Ltd.

AB - Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population. © 2020 Future Medicine Ltd.

KW - ONCOLOGIA

KW - STUDIO CLINICO

KW - RIS

U2 - 10.2217/imt-2019-0180

DO - 10.2217/imt-2019-0180

M3 - Article

VL - 12

SP - 151

EP - 159

JO - Immunother.

JF - Immunother.

SN - 1750-743X

IS - 2

ER -

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

Abstract

Keywords

Access to Document

Fingerprint

Cite this